Neurologi SE’s Post

From a diagnostic standpoint, biochemical support for an Alzheimer's disease diagnosis has become much more available. This development goes hand in hand with the recent developments in the treatment of Alzheimer's disease with anti-amyloid antibodies and other interesting potential treatments that are underway. Henrik Zetterberg, professor at the University of Gothenburg and UCL, gives you his update in this MEDtalk. #Alzheimers 

From a diagnostic standpoint, biochemical support for an Alzheimer's disease diagnosis has become much more available. This development goes hand in hand with the recent developments in the treatment of Alzheimer's disease with anti-amyloid antibodies and other interesting potential treatments that are underway. Henrik Zetterberg, professor at the University of Gothenburg and University College London, gives you his update in this MEDtalk. #Alzheimers 

From a diagnostic standpoint, biochemical support for an Alzheimer's disease diagnosis has become much more available. This development goes hand in hand with the recent developments in the treatment of Alzheimer's disease with anti-amyloid antibodies and other interesting potential treatments that are underway. Henrik Zetterberg, professor at the University of Gothenburg and University College London, gives you his update in this MEDtalk. #Alzheimers 

The BIN1 (amphiphysin protein) is implicated in congenital myopathies, Alzheimer's disease and arrhythmia. Understanding what cellular pathways BIN1 controls is thus of paramount importance. Here, through a tight collaboration with Bogi Zambo, Gergo Gogl and Gilles Travé using quantitative interactomic, we have together revealed and ranked the different protein partners of BIN1. Moreover, we show the impact of BIN1 sequence variants on these interactions. check: https://lnkd.in/e-QvSwba

Interesting MIT article on COVID and Lyme “Long covid looks exactly, and I mean exactly, like chronic Lyme.” - Michal “Mikki” Tal, MIT immunoengineer Although I wouldn't call it 'exactly', as there are many different manifestations of Lyme's Disease (also called the Great Imitator for looking 'exactly' like the majority of any chronic disease... although a better label is the Great Initiator/Facilitator/Originator, as many known chronic diseases have a subset of Lyme patients. E.g. in Alzheimer's Disease; Borrelia in the brain also causes Amyloid-beta plaque that can progress into Alzheimer's Disease, but not all Alzheimer's patients have Borrelia in their brains)... https://lnkd.in/dKqw3fGD #lyme #lymedisease #borrelia #covid #longcovid #persistentlyme

Cogstate Chief Innovation Officer, Prof Paul Maruff, shared data at the recent ADPD meeting showcasing the association between performance on Cogstate tests and biomarkers of Alzheimer’s disease. “These relationships were strong and statistically significant,” said Maruff. “They provide for us now a basis to start to understand the absolute genesis of Alzheimer’s disease, when it begins, and how it manifests.” 📊 View the poster here: https://lnkd.in/edYxJ7hN 🎥 Watch the poster video summary here: https://lnkd.in/ePtPQXjc

From breakthroughs in biomarkers to the resurgence of Alzheimer's disease clinical trials, our latest blog delves into the current landscape and future directions in AD research. Recommend the read! https://bit.ly/4efNsyT

From breakthroughs in biomarkers to the resurgence of Alzheimer's disease clinical trials, our latest blog delves into the current landscape and future directions in AD research. Recommend the read! https://bit.ly/4efNsyT

From breakthroughs in biomarkers to the resurgence of Alzheimer's disease clinical trials, our latest blog delves into the current landscape and future directions in AD research. Recommend the read! https://bit.ly/4efNsyT

From breakthroughs in biomarkers to the resurgence of Alzheimer's disease clinical trials, our latest blog delves into the current landscape and future directions in AD research. Recommend the read! https://bit.ly/4efNsyT